Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Deferred Taxes (2019 - 2021)

Amphastar Pharmaceuticals has reported Deferred Taxes over the past 5 years, most recently at $2.8 million for Q4 2021.

  • Quarterly results put Deferred Taxes at $2.8 million for Q4 2021, down 26.79% from a year ago — trailing twelve months through Dec 2021 was $4.6 million (up 2728.4% YoY), and the annual figure for FY2025 was -$28.7 million, down 260.36%.
  • Deferred Taxes for Q4 2021 was $2.8 million at Amphastar Pharmaceuticals, down from $3.8 million in the prior quarter.
  • Over the last five years, Deferred Taxes for AMPH hit a ceiling of $5.3 million in Q4 2019 and a floor of -$2.0 million in Q3 2020.
  • Median Deferred Taxes over the past 3 years was $2.8 million (2021), compared with a mean of $1.7 million.
  • Biggest five-year swings in Deferred Taxes: dropped 28.71% in 2020 and later dropped 26.79% in 2021.
  • Amphastar Pharmaceuticals' Deferred Taxes stood at $5.3 million in 2019, then dropped by 28.71% to $3.8 million in 2020, then fell by 26.79% to $2.8 million in 2021.
  • The last three reported values for Deferred Taxes were $2.8 million (Q4 2021), $3.8 million (Q4 2020), and -$2.0 million (Q3 2020) per Business Quant data.